Get the latest Venture Capital & Angel investors news and info Join Our Mailing List:

Your Name: 

Your Email:  

*By submitting your name & email you agree to receive for FREE our scholarships & offers Newsletters. You agree also with the storage and handling of your data by this website and 3rd party email services.
You may unsubscribe if you wish. And you can delete your email and name at any time by emailing us to the email on the bottom of this page.

Follow us on
  • NeoVista, Inc. Closes $41 Million in Series C Venture Financing Round

    December 7th, 2006 No comments

    NeoVista, Inc., an ophthalmic device company focusing on the treatment of wet Age-Related Macular Degeneration (AMD), announced recently that the company has successfully closed its third round of private venture financing.

    New investors Essex Woodlands Health Ventures, which led the current round of financing, and MPM Capital, join existing investors Versant Ventures, SV Life Sciences, The Carlyle Group, and Accuitive Medical Ventures. Their investments mark the close of an over-subscribed round of financing for the company.

    “To have received this vote of confidence from new investors like Essex Woodlands Health Ventures and MPM Capital, as well as the continued support of all of our existing investors, shows great promise for our company,” stated John Hendrick, President, and CEO of NeoVista. “I believe it speaks well of our technology that such high quality investment firms are signing on as backers given the current financial climate.”

    Martin Sutter, Managing Director of Essex Woodlands Health Ventures, stated, ”We are pleased to be able to become shareholders of NeoVista, Inc. The Company’s technology offers a very promising approach to the treatment of Wet AMD, with the potential for better long-term visual outcomes than are being observed to date. NeoVista possesses an outstanding senior management team capable of capitalizing on this opportunity.”

    “AMD is one of the most significant unmet medical needs today, and will only grow in the future,” said William Greene, M.D. and General Partner of MPM Capital. “While Lucentis has been a major advance in the treatment of this disease, the need for monthly injections, the cost, and the lack of durable response present real opportunities to provide benefit for patients. NeoVista has an exciting and promising approach, and I look forward to helping the Company achieve its vision.”

    NeoVista, Inc. is currently developing an intra ocular radiation device that shows promising early results in the treatment of Wet AMD. In 2007, the Company intends to enter into a definitive clinical study to support filing for regulatory approval to market the product in the U.S.

    NeoVista, Inc. is a privately held company based in Fremont, CA. The Company, formed in 2002 by The Innovation Factory, has raised over $52M from venture capital sources to date.

    For more information, please visit

Leave a reply

Please leave these two fields as-is:

Protected by Invisible Defender. Showed 403 to 261,252 bad guys.


Latest Headlines:

Friday August 31, 2012
Zscaler Secures $38 Million Investment Round

Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.

Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects

Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding

Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies

Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains

Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster

Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility


By using this website you agree with our cookie policy